Skip to main content
x

Recent articles

Dizal's US first; now what?

Zegfrovy is approved in a best-case setting, but Dizal has no US presence.

M&A analysis: signs of life emerge

Some big deals in the second quarter have raised hopes that takeouts are back.

Regeneron enters the T-cell engager arena

Lynozyfic could have an edge over rival BCMA-targeting bispecifics.

FDA red and green lights: June 2025

Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.

BeOne tries to repeat the inhibitor-degrader double

Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.

The month ahead: July’s upcoming events

Regeneron is facing two FDA decisions for its T-cell engagers.